Should a fasting plasma glucose, hemoglobin A1c, and, if indicated, a 2‑hour oral glucose tolerance test be performed before initiating treatment for polycystic ovary syndrome (PCOS) in a reproductive‑age woman?

Should Glucose Testing Be Done Before Treating PCOS?

Yes, you must perform glucose metabolism screening before initiating PCOS treatment—specifically an oral glucose tolerance test (OGTT) with fasting and 2-hour glucose measurements using a 75-g glucose load, as this is the gold standard and will detect up to 40% of glucose abnormalities that fasting glucose alone would miss 1.

Why OGTT Is Mandatory

The 2013 Endocrine Society guidelines explicitly recommend using an OGTT to screen for impaired glucose tolerance (IGT) and type 2 diabetes in all adolescents and adult women with PCOS because they are at high risk for these abnormalities 1. This is a strong recommendation (Grade 1) based on the recognition that women with PCOS have significantly elevated diabetes risk.

The Problem with Fasting Glucose Alone

Research consistently demonstrates that relying solely on fasting plasma glucose (FPG) is inadequate:

• FPG misses 40% of women with dysglycemia, including all cases of diabetes in some cohorts 2
• The diagnostic agreement between FPG-only screening versus OGTT is poor (κ = 0.103), meaning they identify different patient populations 2
• Even using the recommended FPG cutoff of 5.6 mmol/L has only 48% sensitivity, missing 52% of women with abnormal glucose tolerance 3
• Studies show that 24-25% of women with glucose abnormalities would be missed even with an optimized FPG cutoff of 5.0 mmol/L 4, 3

HbA1c as an Alternative

HbA1c may be considered only if a patient is unable or unwilling to complete an OGTT 1. However, this is a weaker recommendation (Grade 2). While HbA1c shows better diagnostic performance than FPG for detecting abnormal glucose tolerance (sensitivity 76.7% vs 40.5%), it still misses cases that OGTT would detect 5. The 2021 systematic review confirms HbA1c as a substitute screening test only when OGTT is not feasible 6.

Clinical Algorithm for Glucose Screening

At initial PCOS diagnosis:

1. Perform 75-g OGTT with fasting and 2-hour glucose measurements
2. Measure HbA1c only if patient cannot complete OGTT
3. Screen for additional cardiovascular risk factors simultaneously (BMI, waist circumference, blood pressure, lipids) 1

Rescreening frequency:

• Every 3-5 years in stable patients
• More frequently if: central adiposity develops, substantial weight gain occurs, diabetes symptoms appear, or other metabolic risk factors emerge 1

Why This Matters for Treatment Decisions

The glucose metabolism status directly influences treatment selection:

• If IGT or T2DM is present and lifestyle modification fails: Metformin is recommended (Grade 1) 1
• If glucose metabolism is normal: Hormonal contraceptives are first-line for menstrual irregularities and hirsutism/acne 1
• For fertility treatment: Knowing glucose status is critical, as some guidelines contraindicate ovulation induction in certain metabolic profiles 6

Common Pitfalls to Avoid

1. Don't assume normal FPG means normal glucose metabolism—this misses too many cases
2. Don't skip screening in normal-weight women—glucose abnormalities occur regardless of BMI, though less frequently 2
3. Don't delay screening until symptoms appear—PCOS itself confers the risk, independent of other factors
4. Don't use HbA1c as first-line screening—it's acceptable only when OGTT is truly not feasible

The evidence is clear: OGTT before treatment initiation is the standard of care for PCOS, with rescreening at regular intervals throughout the patient's reproductive years and beyond.